| Melissa Bonner |
Melissa Bonner is currently the Senior Vice President-Research at bluebird bio, Inc. She holds a doctorate degree from the University of Delaware and an undergraduate degree from the University of Maryland Baltimore County. |
| Joseph D. Vittiglio |
Joseph D. Vittiglio currently works at American Cancer Society, Inc., as Director, Casa Monte Cassino, Inc, as Director, The Lynnfield Youth Soccer Club, as Director, bluebird bio, Inc., as Chief Business & Legal Officer from 2023, and Gaffin & Krattenmaker PC, as Associate Attorney. Mr. Vittiglio also formerly worked at Oscient Pharmaceuticals Corp., as Director-Corporate Legal Affairs from 2005 to 2007, AMAG Pharma USA, Inc., as Secretary, Flexion Therapeutics, Inc., as Vice President-Legal Affairs & General Counsel in 2015, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, as Senior Associate from 1998 to 2005, AVEO Pharmaceuticals, Inc., as Secretary, Senior Vice President & General Counsel from 2014 to 2015, AMAG Pharmaceuticals, Inc., as Secretary, Chief Business Officer & Executive VP in 2020, and Finch Therapeutics Group, Inc., as Secretary, Chief Business & Legal Officer from 2021 to 2022. Mr. Vittiglio received his undergraduate degree from Tufts University and graduate degree in 1996 from Northeastern University School of Law. |
| Nick Leschly |
Nick Leschly was the founder of Medxtend Corp., where he served as the Chief Executive Officer from 1999 to 2001. He is currently the Chief Executive Officer of FierceBiotech and the Chairman of 2seventy Bio, Inc. He also holds the position of Director at the Biotechnology Innovation Organization. In addition, Mr. Leschly is a Director at bluebird bio, Inc., an Independent Director at Synlogic Operating Co., Inc., and an Independent Director at Synlogic, Inc. In his former roles, Mr. Leschly served as a Director at Proclara Biosciences, Inc. and Edimer Pharmaceuticals, Inc. He was also the Chief Business Officer at Agios Pharmaceuticals, Inc. From 2007 to 2009, he worked as a Partner at Third Rock Ventures LLC. Mr. Leschly completed his undergraduate studies at Princeton University and holds an MBA from The Wharton School of the University of Pennsylvania. |
| Richard Colvin |
Richard Colvin is currently the Chief Medical Officer at bluebird bio, Inc. He previously worked as an Executive Director-Translational Medicine at Novartis, Inc. Dr. Colvin completed his undergraduate degree at Cornell University and obtained a doctorate from Duke University School of Medicine. |
| Anne-Virginie Eggimann |
Anne-Virginie Eggimann is currently an Independent Director at Codiak BioSciences, Inc. and the Chief Regulatory Officer at bluebird bio, Inc. He previously worked as an Executive Director at Voisin Consulting, Inc. Mr. Eggimann has a graduate degree from the University of California, Los Angeles and an undergraduate degree from the California Institute of Technology. |
| Christopher Stanley Krawtschuk |
Christopher Stanley Krawtschuk is currently the Director at Draximage UK Ltd. and the Chief Financial Officer at bluebird bio, Inc. Previously, he held positions as the Managing Director at PricewaterhouseCoopers International Ltd., VP-Lead Divisional Controller at Pfizer Inc., and Chief Financial Officer at Jubilant Pharma Holdings, Inc. He completed his undergraduate degree at William Paterson University. |
| Andrea Walton |
Andrea Walton is currently the Chief People & Culture Officer at bluebird bio, Inc. Her former position was also as Chief People & Culture Officer at Edmentum, Inc. She obtained an undergraduate degree and an MBA from the University of Phoenix. |
| Thomas J. Klima |
Thomas J. Klima is currently the Chief Operating & Commercial Officer at bluebird bio, Inc. He previously held positions as the Senior Director-Marketing at Dendreon Corp. from 2009 to 2012, the Chief Commercial Officer & Senior Vice President at Navidea Biopharmaceuticals, Inc. from 2015 to 2017, and the Chief Commercial Officer at Gamida Cell Ltd. from 2019 to 2020. He obtained his undergraduate degree from Western State College of Colorado. |
| Mark L. Vachon |
Mark L. Vachon is currently serving as the Chairman at bluebird bio, Inc., Director at Klockner Pentaplast of America, Inc., Director at Assistive Technology Group, Inc., Director at Medical Imaging Technology Associates, Director at Kleopatra Holdings 2 SCA, Director at Numotion Corp., Director at Panoramic Health LLC, Trustee at Northeastern University, Member at Center for Corporate Innovation, Inc., and Member at Metropolitan Milwaukee Association of Commerce. Previously, he held positions such as President & Chief Executive Officer-Americas at GE Healthcare, Inc., EVP-Sales, Integration & Operations at Change Healthcare Holdings, Inc., Chief Financial Officer & Executive Vice President at GE Healthcare Ltd. (United Kingdom), and Principal at GE Plastics Europe BV, NBC General Electric, and General Electric Appliances, Inc. Mr. Vachon obtained a graduate degree from Boston College and an undergraduate degree from Northeastern University in 1982. |
| Andrew Obenshain |
Andrew Obenshain is currently the President, Chief Executive Officer & Director at bluebird bio, Inc. since 2021. He is also currently serving as a Director at bluebird bio (UK) Ltd. since 2017. Previously, he worked as the General Manager-Finance at Shire France SAS. Mr. Obenshain completed his undergraduate degree at Dartmouth College and holds an MBA from Kellogg School of Management. |
| John O. Agwunobi |
John O. Agwunobi currently works at The Ensign Group, Inc., as Director from 2023, Oration PBC, as Director, bluebird bio, Inc., as Independent Director from 2017, and US African Development Foundation, as Director from 2008. Dr. Agwunobi also formerly worked at Herbalife Ltd., as Chairman & Chief Executive Officer from 2021 to 2022, Magellan Health, Inc., as Independent Director from 2014 to 2019, ShopKo Stores Operating Co. LLC, as Director, World Health Organization (United States), as Executive Director, Smart Rx Systems, Inc., as Director, Herbalife International, Inc., as Co-President, Chief Health & Nutrition Officer, Walmart, Inc., as Senior Vice President, President-Health & Wellness in 2014, State of Florida, as Secretary-Health Department in 2005, and US Department of Health & Human Services (DC), as Assistant Secretary-Health from 2005 to 2007. Dr. Agwunobi received his graduate degree from The Johns Hopkins University and Masters Business Admin degree from Georgetown University. |
| Charlotte Jones-Burton |
Charlotte Jones-Burton is the founder of Women of Color in Pharma. She is currently an Independent Director at bluebird bio, Inc. . She previously worked as the VP, Global Head-Clinical Development & Nephrology at Otsuka Pharmaceutical Development & Commercialization, Inc. and as the VP-Global Clinical Development & Head-Nephrology at Otsuka Pharmaceuticals (U.K.) Ltd. In 2022, she held the position of Senior VP-Product Development & Strategy at Chinook Therapeutics, Inc. Dr. Jones-Burton completed her undergraduate studies at Washington University in St. Louis. She also obtained graduate and doctorate degrees from the University of Maryland School of Medicine. |
| Najoh Tita |
Najoh Tita is currently serving as an Independent Director at bluebird bio, Inc., Director at CMI Marketing, Inc., and Director at Room To Read. In the past, Tita has worked as the Chief Marketing Officer & Executive Director at Hero AG, General Manager-Western Europe at Merck & Co., Inc., Vice President-Country Division at Bayer Plc, and Global Chief Marketing Officer at Logitech, Inc. Tita completed an undergraduate degree at Spelman College and an MBA at The Fuqua School of Business. |
| Elisabeth Leiderman |
Elisabeth Leiderman is an Independent Director at bluebird bio, Inc. and a Non-Executive Director at Autolus Therapeutics Plc. She previously worked as an Executive Director at Nomura Securities, Inc., VP-Business & Corporate Development at Fortress Biotech, Inc., Chief Business Officer at Complexa, Inc., Chief Financial & Accounting Officer at Decibel Therapeutics, Inc., and Chief Financial & Business Officer at Atsena Therapeutics, Inc. Dr. Leiderman holds an undergraduate degree from the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from Sackler School of Medicine. |
| Richard A. Paulson |
Richard A. Paulson is currently the President, CEO & Director at Karyopharm Therapeutics, Inc. He is also an Independent Director at bluebird bio, Inc. Additionally, he holds positions as a Director at Pharmaceutical Research & Manufacturers of America and Precision Machined Products Association, Inc. Mr. Paulson previously served as the Chief Executive Officer-North America & EVP at Ipsen SA and as the Director & Chief Executive Officer-North America at Ipsen Biopharmaceuticals, Inc. He was also the General Manager at AMGEN GmbH and the Vice President & GM-Oncology Business Unit at Amgen, Inc. Prior to that, he held the position of General Manager-South Africa & Czech Republic at Pfizer Inc. Mr. Paulson has an MBA from the University of Toronto and an undergraduate degree from the University of Saskatchewan. |
